MICHELLE PAPA: Open Payments
NPI 1013042431 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,612 in 177 payments from 38 companies in 2025. Trend: 2023 $5,076 · 2024 $3,664 · 2025 $3,612
Food & beverage: $3,257Consulting: $355
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $450 |
| Novo Nordisk AS | 1 | $355 |
| Otsuka America Pharmaceutical, Inc. | 18 | $267 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $219 |
| Alkermes, Inc. | 9 | $207 |
| AstraZeneca Pharmaceuticals LP | 5 | $182 |
| Ardelyx, Inc. | 9 | $167 |
| PFIZER INC. | 14 | $162 |
| Novo Nordisk Inc | 9 | $161 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $133 |
Products named: REXULTI, CAPLYTA, LYBALVI, JARDIANCE, IBSRELA, QULIPTA, AIRSUPRA, NURTEC ODT.
Industry payments across DE — which companies pay providers there.
